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Although  outbreaks  of  Hand,  Foot,  and Mouth  Disease  (HFMD)  in  young  children  have  long  been  rec-
ognized  worldwide,  the  occurrence  of  rare  and  life-threatening  neurological,  respiratory,  and  cardiac
complications  has  propelled  this  common  condition  into  the  spotlight  as a major  public  health  prob-
lem  in  the affected  countries.  Various  enteroviruses  cause  HFMD,  but  the  severe  complications  have
been  mostly  associated  with  enterovirus  71  (EV71).  Medical  treatment  is supportive  and  measures  to
interrupt  transmission  have  been  challenging  to implement.  Preventive  vaccines  could  have  an  impor-V71 vaccine
eutralizing antibody
tant  clinical  impact,  especially  among  children  younger  than 3  years  old  who are  most  susceptible  to the
neurological  complications.  Several  groups  in  the  highly  affected  Asia-Paciﬁc  region  are  working  towards
vaccines  against  EV71  and  some  candidates  have progressed  to late-stage  clinical  trials  with  two  vaccines
recently  reported  to  have  been  approved  by the regulatory  authorities  in  China.  This  report  summarizes
current  issues  and  progress  in the  development  of  vaccines  against  EV71.
 Orga© 2016  World  Health
Enterovirus 71 (EV71) – a single-stranded RNA virus of the
icornavirus family – is one of the most common causes of Hand,
oot and Mouth Disease (HFMD) outbreaks. It may  be accompa-
ied by rare but life-threatening neurological and cardiopulmonary
omplications. Other enteroviruses cause HFMD as well but in
 more limited distribution. The largest outbreaks typically have
een traced to either Coxsackievirus A16 (CA16) or enterovirus
1 (EV71) [1,2]. Although CA16 is more prevalent, EV71 is more
eurotropic—associated with severe neurological manifestations
nd death. EV71 was ﬁrst isolated in 1969 in the United States
rom a child who died of encephalitis [3]. Since that time, out-
reaks have erupted sporadically across the world. From the
ate 1990s onwards, however, the largest EV71 epidemics have
ccurred almost exclusively in the Asia-Paciﬁc region, including
aiwan, mainland China, Hong Kong, Malaysia, Vietnam, Singapore,
nd Thailand [2,4,5]. A recent study from the Chinese National
nhanced Surveillance System, characterizing the epidemiology of
FMD, found that, from 2008 to 2012, more than 7.2 million cases
f HFMD were reported. Between 2010 and 2012, there were 1.2
ases per 1000 person-years and 500–900 deaths each year [6].
hildren less than 5 years old had the highest risk of disease, and
ge-speciﬁc incidence and mortality rate was  highest in the 12
o 23 month age-group (38.2 cases per 1000 and 1.5 deaths per
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100,000 in 2012). Similar to other affected countries, incidence was
lowest among infants younger than 6 months, older children (age
5–14 years) and adults (age ≥15 years). These data are generally
consistent with other studies that ﬁnd about 50–80% of children
are seropositive for EV71 by the time they reach 5 years of age
[7–9].
EV71 is highly contagious and transmitted through close con-
tact with bodily ﬂuids such as nasopharyngeal secretions and stool.
Children from age 6 months to 5 years are at highest risk of infec-
tion. The disease usually presents with fever, oral lesions (that can
sometimes be severe), and a papulovesicular or maculopapular
exanthem on the palms of the hands, soles of the feet, buttocks,
knees, and elbows. The illness is usually self-limiting but can be
associated with more serious complications. Brainstem encephali-
tis is considered a hallmark of severe HFMD, although a spectrum
of neurological manifestations ranging from aseptic meningitis to
acute ﬂaccid paralysis have been observed. Further progression
to respiratory distress, pulmonary edema, and cardiorespiratory
failure can often be fatal. Early recognition of cases at high risk
of developing serious systemic disease is one of the clinical chal-
lenges of this condition. Some warning signs and risk predictors
of progressing to severe disease have been described in studies
conducted during outbreaks, including severity and duration of
fever, vomiting, lethargy, agitation or irritability [10]. More spe-
ciﬁc neurological signs become more prominent with increasing
severity and have been used in some studies to guide the manage-
ment of cases according to the stage of disease severity [11]. This is
important as close monitoring of those with signs of neurological
ss article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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nvolvement is critical to patient treatment, clinical management
nd prognosis.
Even if the patient recovers, there remains a high likelihood of
hronic neurological sequelae and, in the case of children, severe
evelopmental deﬁciencies. Although smaller-scale outbreaks of
FMD are well-recognized in pediatric populations, it is the larger
utbreaks with serious neurological, respiratory and cardiac man-
festations and occasional fatalities that have galvanized serious
oncern within both lay and public health communities. Such out-
reaks are often associated with a high rate of hospitalization,
lacing pressure on already stressed and under-resourced local
ealthcare systems in affected countries. A recent cost-burden
tudy in China estimates that the annual economic burden of
ild EV71-associated HFMD is about $161–323 million. This esti-
ate does not account for the costs associated with severe and
atal illness, long-term sequelae and cases managed outside of the
ealthcare system [12].
As enteroviruses are RNA viruses, they are prone to a high rate
f mutation and recombination. EV71 can be classiﬁed into three
enotypes – A, B, and C – and 11 genetic subtypes. Genetic anal-
ses often show genotypes changing over time through genetic
ivergence and recombination. The recent outbreaks in mainland
hina, Taiwan and Vietnam have been dominated by subtypes C4
nd C5 in contrast to B4 and B5 in Malaysia and Singapore. Surveil-
ance efforts in Europe have found genotype B and subtypes C1, C2,
nd C4 to be most commonly in circulation. No subtype-speciﬁc
equences related to increased virulence have yet been identiﬁed.
rom a vaccinology perspective, however, animal studies indicate
hat there is broad cross-neutralization across EV71 subtypes. Cur-
ently, no clinical feature or rapid diagnostic test can distinguish
etween EV71 and the other less virulent enteroviruses, or reliably
redict which child will progress to severe HFMD. Conﬁrmatory
iagnosis, based on tissue culture and virus isolation, does not
dequately meet the needs of urgent clinical decision-making. Anti-
en capture and PCR assays are more available now and allow
or more rapid diagnosis, but are not yet widely used due to cost
onstraints and concerns about sufﬁciently high test performance
tandards (i.e., sensitivity and speciﬁcity). Serology can also be used
or EV71 diagnosis but, given the need for acute and convalescent
era, this diagnostic method may  not be helpful in clinical or public
ealth management of the disease. Treatment is mostly support-
ve as there are no targeted therapies available. Although recent
utbreaks of severe HFMD have been largely limited to the Asia-
aciﬁc region, HFMD caused by EV71 or CVA16 have been shown
o be globally distributed [13], with seroprevalence rates rising
harply in children 5 years and above [14]. Overall these data sug-
est that preventive interventions targeted towards infants and
hildren between 6 months and 5 years old will have the great-
st global impact on HFMD disease burden and complications. A
accine would particularly beneﬁt children younger than 3 years
ho are the most susceptible to neurological complications [15].
. Biological feasibility for vaccine development
Seroprevalence studies suggest that maternally-derived anti-
odies, like most other infectious diseases, play an important role in
eonatal and early immunity, protecting infants from EV71 disease
uring the ﬁrst months of life but wane after 6 months of age to a
adir at 7–12 months [16]. The epidemiologic correlation between
aternal antibody titers and risk of HFMD suggests deﬁnable
orrelates of protection that can be induced by vaccines. Addition-
lly, the availability and success of vaccination campaigns against
nother enterovirus, poliovirus, provides strong evidence for the
easibility of developing a vaccine against EV71. In fact, following a
arge-scale epidemic in Bulgaria in 1975, an inactivated whole virus 34 (2016) 2967–2970
EV71 vaccine candidate was developed and produced in the former
Soviet Union, using a similar manufacturing process as that for
the inactivated poliovirus vaccine. The vaccine was tested in 1–4
year old children and found to be safe and immunogenic [17] but
was not evaluated for clinical efﬁcacy as no subsequent outbreaks
occurred in Bulgaria. Following the emergence of EV71-associated
HFMD as a serious public health problem in the Asia-Paciﬁc region,
several groups in mainland China, Taiwan, and Singapore, are
pursuing the development of an EV71 vaccine. Three vaccine man-
ufacturers from mainland China have completed Phase 3 efﬁcacy
trials and applied for licensure approval from the China Food and
Drug Administration in the end of 2014. All three have developed
vaccines based on the inactivated whole virus approach, similar
to the polio vaccine. Large, multi-center trials, Phase 3 trials (each
enrolling more than 10,000 children), in either 6–35 month or 6–71
month age groups have shown similar safety and efﬁcacy proﬁles,
achieving more than 90% protection from EV71-associated HFMD.
Despite the demonstration of efﬁcacy in these trials, an EV71
vaccine still runs into the challenge of preventing and control-
ling not just EV71-associated HFMD but all-cause clinical HFMD.
As expected from previous preclinical studies, the vaccines that
have been developed, thus far do not demonstrate any evidence
of cross-protection across enterovirus species. As it happens, EV71
did not turn out to be the dominant cause of the HFMD outbreaks
and that in two  of the trials, and only a small proportion of the total
HFMD cases were caused by EV71 when conﬁrmed by laboratory
diagnosis. Of the 1704 cases of HFMD diagnosed clinically over 12
months of follow-up in one of the Phase 3 trials, only 36 (2.1%) were
conﬁrmed as being associated with EV71 [18]. The remainder of eti-
ologies included 33.9% (577 episodes) positive for CA16, 34.5% (588
episodes) positive for other enteroviruses and 29.5% (503 episodes)
not associated with any enterovirus. Thus, for every episode of
EV71, there were 11 episodes of CA16. In contrast, in another trial,
of the 594 cases of clinical HFMD, 155 (26%) were lab-conﬁrmed
EV71. Although the vaccine was  not cross-reactive against other
subtypes, vaccine efﬁcacy against clinical HFMD was 49% (39–56)
[19]. All three vaccines were immunogenic, achieving geometric
mean antibody titers of 165.8 (Sinovac; 400 U/two-dose), 170.6
(Chinese Academy Medical Sciences; 100 U/two-dose), and 325.3
(Beijing Vigoo; 320 U/two-dose) and inducing seroconversion in
>90% of subjects [18–20]. Although neutralizing antibody titers
waned through 8 months of follow-up post-boost, they remained
stable between 8 and 14 months, were still higher than at baseline
and were signiﬁcantly higher than titers in the placebo group.
Formulating vaccination policy will be difﬁcult, given the chal-
lenges in justifying clinical beneﬁt in an HFMD epidemic where
EV71 is not the dominant strain. Careful thought and preparation
will be required to help parents and the public understand that
while such vaccines might prevent severe or fatal HFMD, they may
offer no protection against HFMD caused by other enteroviruses.
The results also underline the importance of CA16 in the HFMD
disease burden: thus an effective HFMD vaccine might have to at
least be bivalent. Additional constraints on EV71 vaccine develop-
ment include the lack of an appropriate animal model, the need for
more knowledge on virus transmission, epidemiology and disease
burden, and an assessment of health care burden and costs for the
prevention, treatment and control of an HFMD epidemic.
2. Technical and regulatory assessment
EV71 vaccines have been developed and tested outside the tradi-
tional drug and vaccine pipeline, which normally involves a mature
regulatory infrastructure that has experience not only in the devel-
opment and enforcement of quality control standards, but also in
the conduct and review of clinical trial data and the drafting of
Z. Reed, M.J. Cardosa / Vaccine 34 (2016) 2967–2970 2969
Table  1
Development status of current vaccine candidates (POC = Proof of concept trial).
Candidate Name/Identiﬁer Phase I Phase II POC Phase III
Vero cell–based EV71 inactivated EV71 C4 genotype vaccine with aluminum
hydroxide/Sinovac Biotech
X
Human diploid-cell line (KMB17 strain) inactivated EV71 C4 genotype vaccine with
aluminium hydroxide/Chinese Academy of Medical Sciences (CAMS)
X
Vero cell–based EV71 inactivated EV71 C4 genotype vaccine with aluminum
hydroxide/Beijing Vigoo
X
Vero cell–based EV71 inactivated vaccine B4 sub-genotype with Alum (AlPO4)/Taiwanese
National Health Research Institute (NHRI) [24,25]
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olicy on the introduction and use of novel vaccines. Mainland
hina, Taiwan and Singapore have more limited experience in these
reas, although there are ongoing efforts, particularly in mainland
hina by the Chinese Drug Administration, to develop reference
tandards in a transparent manner and harmonize local, regional
nd international quality control requirements for EV71 vaccines.
ecently, the WHO  ECBS approved a joint initiative between the
ational Institutes for Food and Drug Control and National Insti-
ute for Biological Standards and Control to develop quantitative
tandards for detecting EV71 neutralizing antibodies and antigens
ith the purpose of developing candidate vaccines. Similar to polio
accines, neutralizing antibody titers may  serve as a good correlate
f protection for EV71 vaccines. Two of the Phase 3 trials discussed
reviously provided evidence that neutralizing antibodies corre-
ated with protection at levels titers of 1:16 to 1:32. Furthermore,
xperience from polio vaccines also show that there is variability in
he induction of neutralizing antibody responses that result from
he several antigenic formats following the production of inactiv-
ted whole virus. Therefore the development of reference reagents
nd establishment of harmonized assays that measure the consis-
ency and potency of the vaccines are critical for the assessment of
hese vaccines not only in China but also by regulatory authorities
n other regions.
Although detailed cost-effectiveness analyses are not widely
vailable, one study has suggested that routine EV71 vaccination in
hina, with a background incidence of 0.04%, may  be cost-effective
f vaccine efﬁcacy is ≥70%, and the vaccine costs $25 or less, or
f vaccine efﬁcacy is ≥50% and the vaccine costs $10 or less [21].
igher infection incidence and vaccine efﬁcacy were observed in
he cited Phase 3 efﬁcacy trials. It is estimated that, based on rates
nd outcomes observed in these trials, immunization would be
ost-effective. Policies on the use of these vaccines will also need to
onsider if and how the EV71 vaccine would be introduced into a
overnment’s national immunization program as well as catch-up
ampaigns. In addition, given the epidemic nature of the condition,
onsiderations will also have to be made for the use of these vac-
ines in outbreak settings and how their effectiveness would be
ubsequently evaluated.
The use of an EV71 vaccine may  impact natural transmission
f wild EV71 virus and change its epidemiological characteristics
22]. Surveillance and monitoring will be required to determine
isease rates in the aftermath of vaccine deployment. Evaluation of
V71 epidemiology and pathogenicity will also have to take place
n the context of HFMD as a whole in addition to HFMD speciﬁ-
ally caused by EV71. Therefore, the laboratory-based surveillance
ystem will have to be strengthened to adequately monitor preva-
ent strains and strain variation. Some groups are already moving
oward the next step of vaccine development for HFMD, multiva-
ent and combination vaccines. The latter may  be a viable approach
o broadening coverage with the inclusion of multiple enterovirus
pecies that cause HFMD. This strategy is being pursued by sev-
ral groups, some of whom are developing bivalent HFMD vaccinesX
with either the inactivated whole viruses or virus like particles
(VLPs). However this will require additional characterization of the
disease burden, pathogenic spectrum and virological and molecu-
lar features of additional enteroviral targets. Although the legacy
of the polio vaccines may  provide lessons for combination vac-
cine approaches, there will be additional technical and regulatory
requirements that will need to be taken into account.
3. Status of vaccine R&D activities
Various approaches have been pursued in the research develop-
ment pipeline for EV71 vaccines, including live attenuated viruses,
inactivated whole viruses, VLPs, and recombinant protein subunits.
As described earlier, the most advanced candidates are inactivated
whole virus vaccines that have leveraged previous knowledge and
experience from the development and manufacturing of inactiv-
ated polio vaccines. Most of the other approaches are at the stage of
early or late preclinical development. Five candidate vaccines have
reached clinical evaluation, all inactivated whole viruses. The three
groups in mainland China that have developed inactivated whole
virus vaccines beneﬁted from the priority placed by the Chinese
government on developing an EV71-HFMD vaccine in the after-
math of the 2008 outbreaks. This has led to a vaccine development
agenda that is highly coordinated among national vaccine man-
ufacturing agencies in the most affected regions. With a fast-track
provided by regulators, all three Chinese companies have been able
advance rapidly from ﬁrst-in-human studies to Phase 3 trials in
less than 18 months and out of these, two have received regula-
tory approval to manufacture and market their vaccine in China.
The vaccine manufacturers are also working with the regulatory
authorities to develop standards that will allow for the comparison
of the potency and immunogenicity of the respective vaccine candi-
dates. Outside of mainland China, similar vaccines (e.g., inactivated
EV71 virus in an alum adjuvant) are being developed in Taiwan
and Singapore. The National Health Research Institute in Taiwan
is producing an inactivated whole virus vaccine based on the B4
genotype vaccine strain. The vaccine entered Phase I clinical tri-
als in 2010 and showed the induction of 4-fold or greater rise in
neutralization antibody titers in healthy adults after the ﬁrst vac-
cination. Inviragen of Singapore completed Phase 1 testing of a
vaccine based on the B3 subtype that also demonstrated immuno-
genicity. No further progress has been reported on these candidates
following completion of their Phase 1 trials (Table 1).
An alternate to the inactivated virus approach is the develop-
ment of VLP vaccines, which offer the advantage of presenting all
surface epitopes of the EV71 capsid proteins (VP0, VP1, and VP3)
in their native conformations at once. Experimental animal model
immunization and challenge studies have indicated that VLPs can
generate protective neutralizing antibodies. Importantly, studies
have also demonstrated that neutralizing antibodies induced by
vaccination were cross-reactive against multiple subtypes that
were not in the vaccine [23]. Most of these efforts are currently in
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he preclinical stages. Live attenuated recombinant subunits, pep-
ides and DNA approaches been described in the literature but to
ur knowledge these approaches are not being pursued by vaccine
evelopers.
. Summary
The three formalin-inactivated EV71 vaccines tested in Phase
 trials in China have reported a high-degree of efﬁcacy. Two
accines have received regulatory approval and EV71-associated
FMD could become a vaccine-controllable disease in China.
s EV71 vaccine development in LMICs is aimed at protecting
nfants and children less than 5 years of age, the vaccines could
e considered within the scope of GAVI’s mission. However,
he lack of cross-species activity complicates vaccine introduc-
ion campaigns and could limit their acceptance for widespread
mplementation. Improved understanding of the epidemiology
nd transmission dynamics of EV71 speciﬁcally and other HFMD-
ausing enteroviruses generally is needed to power efﬁcacy trials
s well as to assess vaccine impact. The development of HFMD vac-
ines that cover the multiple viral etiologies through multivalent
pproaches is underway and could expand the clinical and public
ealth impact of the next-generation vaccines for HFMD.
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